Ulcerative Colitis Study
November 17, 2014
Remington-Davis is working with Dr. Cordasco and Incyte Corporation to find volunteers with a history of Ulcerative Colitis, to participate in a clinical research study. The purpose of the study is to evaluate how well an investigational drug, itacitinib, works and evaluate its safety in patients with moderate to severe UC.
If you are interested you should:
- Be 18-85 years of age
- Have a confirmed diagnosis of Ulcerative Colitis
- Currently receiving medications to treat Ulcerative Colitis
- Active Ulcerative Colitis symptoms
Eligible patients will be randomly assigned to itacitinib OR a placebo. You have a two (2) in three (3) chance of receiving the investigational drug and a one (1) in three (3) chance of receiving the placebo. The study is blinded which means that neither you nor the study staff will know which treatment you are receiving, although, this information would be made available in case of an emergency.
If you are interested in volunteering and qualify for this study, you will come to the study center for up to 6 visits in approximately 5 months. Visits may include physical exams, EKG’s, blood draws, and questionnaires. You will also complete an electronic diary at home to record your ongoing symptoms. A colonoscopy (preferably) or sigmoidoscopy procedure will be performed at different times in the study. Study required medical procedures and the investigational drug will be provided at no cost to you. You may also be eligible for a 40-week open label extension trial where you would be given investigational drug (itacitinib) regardless of what you received during the first portion of the study. You would be compensated for travel expenses per completed visit for your participation in this study.
For more information, please call our office at (614) 487-2560 or email us at email@example.com.